NO20070049L - Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese - Google Patents

Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese

Info

Publication number
NO20070049L
NO20070049L NO20070049A NO20070049A NO20070049L NO 20070049 L NO20070049 L NO 20070049L NO 20070049 A NO20070049 A NO 20070049A NO 20070049 A NO20070049 A NO 20070049A NO 20070049 L NO20070049 L NO 20070049L
Authority
NO
Norway
Prior art keywords
disorders
angiogenesis
treatment
derivatives useful
pyrrolotriazine derivatives
Prior art date
Application number
NO20070049A
Other languages
English (en)
Norwegian (no)
Inventor
Harold Clinton Eugene Kluender
Julie A Dixon
Catherine Brennan
Karl Miranda
Brent Chandler
Barton Phillips
Jianmei Fan
Michael Brands
Andrea Mcclure
Benjamin Jones
Wenlang Fu
Donald Bierer
Steven Magnuson
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070049(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20070049L publication Critical patent/NO20070049L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20070049A 2004-06-03 2007-01-03 Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese NO20070049L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57665204P 2004-06-03 2004-06-03
US62653104P 2004-11-09 2004-11-09
PCT/US2005/019472 WO2005121147A1 (en) 2004-06-03 2005-06-03 Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Publications (1)

Publication Number Publication Date
NO20070049L true NO20070049L (no) 2007-01-30

Family

ID=34971944

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070049A NO20070049L (no) 2004-06-03 2007-01-03 Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese

Country Status (30)

Country Link
US (3) US7563791B2 (pt)
EP (1) EP1765823B1 (pt)
JP (1) JP4958772B2 (pt)
KR (1) KR101235602B1 (pt)
CN (1) CN1993361B (pt)
AR (1) AR049138A1 (pt)
AT (1) ATE462708T1 (pt)
AU (1) AU2005252217B2 (pt)
BR (1) BRPI0510848A (pt)
CA (1) CA2569396C (pt)
DE (1) DE602005020293D1 (pt)
EC (1) ECSP067043A (pt)
ES (1) ES2342722T3 (pt)
GT (1) GT200500137A (pt)
HN (1) HN2005000255A (pt)
IL (1) IL179264A0 (pt)
MA (1) MA28689B1 (pt)
MX (1) MX279139B (pt)
MY (1) MY145077A (pt)
NO (1) NO20070049L (pt)
NZ (1) NZ551742A (pt)
PE (1) PE20060243A1 (pt)
PH (1) PH12006502386B1 (pt)
RU (1) RU2401269C2 (pt)
SG (1) SG127661A1 (pt)
SV (1) SV2006002134A (pt)
TW (1) TW200608979A (pt)
UY (1) UY28931A1 (pt)
WO (1) WO2005121147A1 (pt)
ZA (1) ZA200700011B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
ME00011A (me) 2005-12-21 2009-02-10 Novartis Ag Derivati pirimidinilaril uree kao fgf inhibitori
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
US7912582B1 (en) * 2007-05-03 2011-03-22 Innovation Associates, Inc. Robotic prescription filling system
EP2195286A2 (en) 2007-09-10 2010-06-16 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
MX2010003269A (es) * 2007-09-25 2010-08-02 Bayer Healthcare Llc Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
EP2739144A4 (en) * 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc COMPOUNDS AND ITS THERAPEUTIC USE
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
CA2862981C (en) 2011-12-15 2020-02-25 Bayer Pharma Aktiengesellschaft Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
ES2750791T3 (es) * 2014-06-17 2020-03-27 Chiesi Farm Spa Derivados de indolizina como inhibidores de fosfoinositido 3-quinasas
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
AU2017228398A1 (en) 2016-03-03 2018-10-18 Cornell University Small molecule IRE1-alpha inhibitors
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
SG11202111244XA (en) 2019-04-12 2021-11-29 Blueprint Medicines Corp Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
ES3065954T3 (en) * 2019-05-13 2026-05-08 Relay Therapeutics Inc Fgfr inhibitors and methods of use thereof
CN112552302B (zh) * 2019-09-26 2022-05-13 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
US12534479B2 (en) * 2020-07-10 2026-01-27 Findcure Biosciences (Zhongshan) Co., Ltd. Triazine compound and composition and use thereof
TWI924727B (zh) 2020-11-18 2026-05-11 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
JP7891524B2 (ja) 2021-08-11 2026-07-16 バイオメア フュージョン，インコーポレイテッド 真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤
MX2024002189A (es) 2021-08-20 2024-06-11 Biomea Fusion Inc Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer.
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2097384C1 (ru) * 1989-10-31 1997-11-27 Биокрист Фармасьютикалз Инк. Производные 2-амино-7-(chr2r3)-3н,5н-пирроло[3,2-d]-пиримидин-4-она, способы их получения и способ селективного ингибирования пролиферации т-лимфоцитов млекопитающего и не оказывающий воздействия на b-лимфоциты
IL144977A0 (en) * 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
AU3276002A (en) * 2000-11-17 2002-05-27 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
MX2010003269A (es) 2007-09-25 2010-08-02 Bayer Healthcare Llc Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.

Also Published As

Publication number Publication date
JP4958772B2 (ja) 2012-06-20
AU2005252217A1 (en) 2005-12-22
ZA200700011B (en) 2008-11-26
HN2005000255A (es) 2010-09-17
ATE462708T1 (de) 2010-04-15
WO2005121147A1 (en) 2005-12-22
AR049138A1 (es) 2006-06-28
SV2006002134A (es) 2006-10-04
CN1993361B (zh) 2010-05-26
ECSP067043A (es) 2006-12-29
KR20070035028A (ko) 2007-03-29
MX279139B (es) 2010-09-21
PH12006502386B1 (en) 2010-12-23
GT200500137A (es) 2006-05-18
DE602005020293D1 (de) 2010-05-12
MA28689B1 (fr) 2007-06-01
EP1765823A1 (en) 2007-03-28
US20130225809A1 (en) 2013-08-29
PE20060243A1 (es) 2006-04-21
MY145077A (en) 2011-12-15
NZ551742A (en) 2010-08-27
IL179264A0 (en) 2007-03-08
US7563791B2 (en) 2009-07-21
TW200608979A (en) 2006-03-16
RU2401269C2 (ru) 2010-10-10
MXPA06013457A (es) 2007-03-01
UY28931A1 (es) 2005-12-30
US20070208013A1 (en) 2007-09-06
CA2569396C (en) 2011-12-20
KR101235602B1 (ko) 2013-02-21
ES2342722T3 (es) 2010-07-13
JP2008501703A (ja) 2008-01-24
CA2569396A1 (en) 2005-12-22
AU2005252217B2 (en) 2011-05-12
HK1109141A1 (en) 2008-05-30
SG127661A1 (en) 2007-01-30
CN1993361A (zh) 2007-07-04
US8338595B2 (en) 2012-12-25
BRPI0510848A (pt) 2007-11-27
EP1765823B1 (en) 2010-03-31
RU2006147237A (ru) 2008-07-20
US20100075958A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ECSP055783A (es) Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20052380L (no) Beta-amino-heterosykliske dipeptidylpeptidaseinhibitorer for behandling og forhindring av diabetes
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
DE60330485D1 (de) Zur behandlung von diabetes
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
WO2006058064A3 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MX2007004936A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1.
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
WO2004074243A3 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE449604T1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
SE0403006D0 (sv) New compounds
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20064732L (no) Alfa-aminoamidderivater nyttige i behandlingen av urolige bein-syndromet og additive lidelser
NO20080354L (no) Benzofuranylderivater som 5-HT6-reseptorinhibitorer
GB0407025D0 (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application